Associations of Insulin Resistance and Adiponectin With Mortality in Women With Breast Cancer

DOI Web Site 被引用文献2件
  • Catherine Duggan
    From the Fred Hutchinson Cancer Research Center, Seattle, WA; Yale School of Public Health, New Haven, CT; City of Hope National Medical Center, Duarte, CA; National Cancer Institute, Bethesda, MD; and the School of Public Health and Information Sciences, University of Louisville, Louisville, KY.
  • Melinda L. Irwin
    From the Fred Hutchinson Cancer Research Center, Seattle, WA; Yale School of Public Health, New Haven, CT; City of Hope National Medical Center, Duarte, CA; National Cancer Institute, Bethesda, MD; and the School of Public Health and Information Sciences, University of Louisville, Louisville, KY.
  • Liren Xiao
    From the Fred Hutchinson Cancer Research Center, Seattle, WA; Yale School of Public Health, New Haven, CT; City of Hope National Medical Center, Duarte, CA; National Cancer Institute, Bethesda, MD; and the School of Public Health and Information Sciences, University of Louisville, Louisville, KY.
  • Katherine D. Henderson
    From the Fred Hutchinson Cancer Research Center, Seattle, WA; Yale School of Public Health, New Haven, CT; City of Hope National Medical Center, Duarte, CA; National Cancer Institute, Bethesda, MD; and the School of Public Health and Information Sciences, University of Louisville, Louisville, KY.
  • Ashley Wilder Smith
    From the Fred Hutchinson Cancer Research Center, Seattle, WA; Yale School of Public Health, New Haven, CT; City of Hope National Medical Center, Duarte, CA; National Cancer Institute, Bethesda, MD; and the School of Public Health and Information Sciences, University of Louisville, Louisville, KY.
  • Richard N. Baumgartner
    From the Fred Hutchinson Cancer Research Center, Seattle, WA; Yale School of Public Health, New Haven, CT; City of Hope National Medical Center, Duarte, CA; National Cancer Institute, Bethesda, MD; and the School of Public Health and Information Sciences, University of Louisville, Louisville, KY.
  • Kathy B. Baumgartner
    From the Fred Hutchinson Cancer Research Center, Seattle, WA; Yale School of Public Health, New Haven, CT; City of Hope National Medical Center, Duarte, CA; National Cancer Institute, Bethesda, MD; and the School of Public Health and Information Sciences, University of Louisville, Louisville, KY.
  • Leslie Bernstein
    From the Fred Hutchinson Cancer Research Center, Seattle, WA; Yale School of Public Health, New Haven, CT; City of Hope National Medical Center, Duarte, CA; National Cancer Institute, Bethesda, MD; and the School of Public Health and Information Sciences, University of Louisville, Louisville, KY.
  • Rachel Ballard-Barbash
    From the Fred Hutchinson Cancer Research Center, Seattle, WA; Yale School of Public Health, New Haven, CT; City of Hope National Medical Center, Duarte, CA; National Cancer Institute, Bethesda, MD; and the School of Public Health and Information Sciences, University of Louisville, Louisville, KY.
  • Anne McTiernan
    From the Fred Hutchinson Cancer Research Center, Seattle, WA; Yale School of Public Health, New Haven, CT; City of Hope National Medical Center, Duarte, CA; National Cancer Institute, Bethesda, MD; and the School of Public Health and Information Sciences, University of Louisville, Louisville, KY.

抄録

<jats:sec><jats:title>Purpose</jats:title><jats:p> Overweight or obese breast cancer patients have a worse prognosis compared with normal-weight patients. This may be attributed to hyperinsulinemia and dysregulation of adipokine levels associated with overweight and obesity. Here, we evaluate whether low levels of adiponectin and a greater level of insulin resistance are associated with breast cancer mortality and all-cause mortality. </jats:p></jats:sec><jats:sec><jats:title>Patients and Methods</jats:title><jats:p> We measured glucose, insulin, and adiponectin levels in fasting serum samples from 527 women enrolled in the Health, Eating, Activity, and Lifestyle (HEAL) Study, a multiethnic, prospective cohort study of women diagnosed with stage I-IIIA breast cancer. We evaluated the association between adiponectin and insulin and glucose levels (expressed as the Homeostatic Model Assessment [HOMA] score) represented as continuous measures and median split categories, along with breast cancer mortality and all-cause mortality, using Cox proportional hazards models. </jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p> Increasing HOMA scores were associated with reduced breast cancer survival (hazard ratio [HR], 1.12; 95% CI, 1.05 to 1.20) and reduced all-cause survival (HR, 1.09; 95% CI, 1.02 to 1.15) after adjustment for possible confounders. Higher levels of adiponectin (above the median: 15.5 μg/mL) were associated with longer breast cancer survival (HR, 0.39; 95% CI, 0.15 to 0.95) after adjustment for covariates. A continuous measure of adiponectin was not associated with either breast cancer–specific or all-cause mortality. </jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p> Elevated HOMA scores and low levels of adiponectin, both associated with obesity, were associated with increased breast cancer mortality. To the best of our knowledge, this is the first demonstration of the association between low levels of adiponectin and increased breast cancer mortality in breast cancer survivors. </jats:p></jats:sec>

収録刊行物

被引用文献 (2)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ